Trans-differentiation of cancer cells to terminal differentiation via addition of chemical agents i.e. retinoids for acute promyelocytic leukaemia (APL) [111], peroxisome proliferator activated receptor gamma (PPARg) agonists for liposarcoma [112], or epigenetic drugs [113], could potentially be preferable with respect to clinical application compared to classical factor based reprogramming. Here, PPARG is linked to cancer.